You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
远大医药(00512.HK)多种产品被列入2019版医保目录"小儿咳喘颗粒"获首次纳入
格隆汇 08-27 08:18

格隆汇8月27日丨远大医药(00512.HK)公告,近日,集团有多种产品被列入由中华人民共和国国家医疗保障局及人力资源和社会保障部发布的"国家基医疗保险、工伤保险和生育保险药品目录(2019年版)"(2019版医保目录)中,多于2017年版所列入的数目。

特别是集团的核心及主要产品如心脑血管急救用药如盐酸替罗非班和辛伐他汀、眼科药如左氧氟沙星凝胶剂型和马来酸噻吗洛尔滴眼液、五官科药桉柠蒎肠溶软胶囊(品牌名称"切诺"和金嗓系列等领域中的核心产品,仍然被保留在2019版医保目录中。儿童用药作为2019版医保目录优先考虑的品种其中一项,而集团的中药保护品种"小儿咳喘颗粒"凭藉在儿童治疗的安全性和有效性获首次纳入。

此外,集团于2018年完成收购55%股权益的上海旭东海普药业有限公司的"浓氯化钠注射液"也获首次纳入,将为集团进一步扩充心血管领域的药品品种起到积极推动作用。

此次,医保目录的调整是国家医保局成立后首次全面调整,也是自2000年第一版药品目录以来对原有目录品种的一次全面梳理。业界认为此次调整,将有利于提高医保基金使用效率。

经过次全面梳理及调整后,集团仍然有众多产品被列入2019年国家医保目录,证明经过多年的研发、推广和临床应用,集团的产品在治疗有效性、安全性和成效益等方面获得认同,有利于提升企业整体产品的市场地位及品牌知名度。同时,集团将积极应对国家医保目录动态调整所带来的市场变化,通过加快产品结构调整、继续不断提升研发实力、发挥政策利好优势等方式,让更多患者更好地获得集团优质产品带来的用药益处,并因而推动集团的业绩能持续稳定增长并为股东带来更多的回报。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account